


Predicted median PFS

Risk category

Proposed management



LOW RISK

Anti-PD-1 monotherapy

INTERMEDIATE RISK

Anti-PD-1 +/- 1-Line chemotherapy
 Anti-PD-1 +/- anti-CTLA-4 in any line
 (Chemotherapy may be still useful if rapid shrinkage is needed)

POOR RISK

Anti-PD-1 + 1-Line chemotherapy
 Anti-PD-1 + anti-CTLA-4 in any line
 Clinical trials with novel ICI combos

Note: not intended for clinical use